On the issue of cough treatment in COVID-19 patients


DOI: https://dx.doi.org/10.18565/therapy.2022.4suppl.100-103

Ovsyannikov E.S., Feygelman S.N., Alexeeva N.G.

Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russian Federation
Abstract. Unproductive cough is one of the most frequent complaints in COVID-19, therefore, levodropropizine, a peripheral antitussive agent, was prescribed to 98 patients for its treatment (basic group). The comparison group consisted of 29 patients with COVID-19 with the same complaints who voluntarily refused to take the specified drug. As a result of the study, it was found that during 7 days of treatment with levodropropizine, the intensity and severity of dry cough during the day and at night significantly decreased.
Keywords: levodropropizine, antitussive agents, dry cough, novel coronavirus infection COVID-19
Read entire article

Literature

1. Paules C.I., Marston H.D., Fauci A.S. Coronavirus infections – more than just the common cold. JAMA. 2020; 323(8): 707–8. doi: 10.1001/jama.2020.0757.


2. Dicpinigaitis P.V., Morice A.H., Birring S.S. et al. Antitussive drugs – past, present, and future. Pharmacol Rev. 2014; 66(2): 468–512. doi: 10.1124/pr.111.005116.


3. Государственный реестр лекарственных средств Минздрава России. Инструкция по применению лекарственного препарата с МНН леводропропизин. Доступ: https://grls.rosminzdrav.ru (дата обращения – 25.04.2022).


4. Орлова Н.В. Хронический кашель: дифференциальная диагностика и лечение. Медицинский совет. 2020; 17: 124–131. doi: 10.21518/2079-701X-2020-17-124-131.


Similar Articles

Back to Content

Бионика Медиа